TY - JOUR
T1 - Dibenzylxanthines as PPEPCK-M inhibitors for cancer therapy
AU - Aragó, Marc
AU - Rodríguez-Arévalo, Sergio
AU - Moreno, Juan
AU - Abás, Sònia
AU - Figueras, Agnès
AU - Pérez, Belén
AU - Viñals, Francesc
AU - Carmen Escolano, María
AU - Carlos Perales, José
PY - 2019
Y1 - 2019
N2 - Phosphoenolpyruvate carboxykinase (PEPCK) is the key enzyme in gluconeogenesis/glyceroneogenesis, which catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate. In eukaryotes, there are two isozymes present either in the cytosol (PEPCKC, PCK1) or the mitochondria (PEPCK-M, PCK2). While PCK1 is found in gluconeogenic tissues and has a very clear metabolic function, PCK2 is expressed in non-gluconeogenic cell types, where its role remains largely unknown. For example, PCK2 is highly expressed in most cancer cells, where it provides a growth advantage to cancer cells in nutrient-poor environments.
AB - Phosphoenolpyruvate carboxykinase (PEPCK) is the key enzyme in gluconeogenesis/glyceroneogenesis, which catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate. In eukaryotes, there are two isozymes present either in the cytosol (PEPCKC, PCK1) or the mitochondria (PEPCK-M, PCK2). While PCK1 is found in gluconeogenic tissues and has a very clear metabolic function, PCK2 is expressed in non-gluconeogenic cell types, where its role remains largely unknown. For example, PCK2 is highly expressed in most cancer cells, where it provides a growth advantage to cancer cells in nutrient-poor environments.
U2 - 10.3390/proceedings2019022079
DO - 10.3390/proceedings2019022079
M3 - Article
SN - 2504-3900
VL - 22
SP - 1
EP - 1
JO - Proceedings (MDPI)
JF - Proceedings (MDPI)
ER -